+

WO1991011435A3 - NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL - Google Patents

NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL Download PDF

Info

Publication number
WO1991011435A3
WO1991011435A3 PCT/US1991/000018 US9100018W WO9111435A3 WO 1991011435 A3 WO1991011435 A3 WO 1991011435A3 US 9100018 W US9100018 W US 9100018W WO 9111435 A3 WO9111435 A3 WO 9111435A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
trifluoropropyl
oxazolyl
dihydro
cycloalkyl
Prior art date
Application number
PCT/US1991/000018
Other languages
English (en)
Other versions
WO1991011435A2 (fr
Inventor
Hakan Vilhelm Wikstrom
Per Arvid Emil Carlsson
Bengt Ronny Andersson
Kjell Anders Ivan Svensson
Stig Thomas Elebring
Nils Peter Stjernlof
Arthur Glenn Romero
Susanne Renee Haadsma
Chiu-Hong Lin
Michael Dalton Ennis
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK91902598T priority Critical patent/DK0510068T3/da
Priority to EP91902598A priority patent/EP0510068B1/fr
Priority to DE69131123T priority patent/DE69131123T2/de
Priority to JP3502958A priority patent/JP3049089B2/ja
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of WO1991011435A2 publication Critical patent/WO1991011435A2/fr
Publication of WO1991011435A3 publication Critical patent/WO1991011435A3/fr
Priority to US07/907,932 priority patent/US5288748A/en
Priority to KR1019920701635A priority patent/KR100196887B1/ko
Priority to US08/144,857 priority patent/US5461061A/en
Priority to US08/460,449 priority patent/US5650427A/en
Priority to KR1019980710454A priority patent/KR100201012B1/ko
Priority to GR990401483T priority patent/GR3030389T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/62—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles
    • C07D209/66—Naphtho [c] pyrroles; Hydrogenated naphtho [c] pyrroles with oxygen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

L'invention se rapporte à un composé représenté par la formule (I) ou à des sels pharmaceutiquement acceptables du composé de la formule (I), où R1 représente H, un alkyle C¿1?-C3, -(CH2)nCONH2, où n est compris entre 2 et 6, (CH2)n-1-(4,4-diméthylpipéridine-2,6-dione-yle), ou un cyclopropylméthyle; R?2¿ représente l'hydrogène, un alkyle C¿1?-C8, un cycloalkyle C3-C8 ou est combiné avec R?1¿ pour former un cycloalkyle C¿3?-C8, un alcényle C2-C8, un alkynyle C2-C8, (CH2)n-X-Ar, où X représente O, S, ou NH, 3,3,3-trifluoropropyle, -(CH2)m-R?9¿ où m est égal à 2 ou à 3 et R9 représente un phényle, un 2-thiophényle ou un 3-thiophényle; R3 représente un alkyle C¿1?-C3, un 2,2,2-trifluoroéthyle, un 3,3,3-trifluoropropyle, un formyle, CN, un halogène, CH2OR?2¿, C(O)C(O)Y où Y représente OR?1 ou NR1R2¿, -(CH¿2?)q-NR?1R2¿ où q est compris entre 0 et 5, C=NOR2, un 2(4,5-dihydro)oxazolyle, ou COR?10 où R10¿ représente H, R?1, NR1R2¿ ou CF¿3; R?4 représente un alkyle C¿1?-C3, un cyclopropylméthyle, CF3, un 2,2,2-trifluoroéthyle, CN, CONR?1R2¿, =O, un 2(4,5-dihydro)imidazolyle, un 2(4,5-dihydro)oxazolyle, un 2-oxazolyle, un 3-oxadiazolyle, ou un 3,3,3-trifluoropropyle; R5 représente un hydrogène, R1, OCH3, C(O)CH3 ou C(O)OR1; X représente (a) une liaison de valence, (b) CH¿2?, (c) O, S ou NR?5 où R5¿ représente H, un alkyle C¿1?-C8, un cycloalkyle C3-C8, un benzyle, COR?6 où R6¿ représente un alkyle C¿1?-C3, un phényle, ou CONR?7R8 où R7 et R8¿ représentent séparément H ou un alkyle C¿1?-C3, et Z représente un hydrogène ou un halogène. Ces composés représentés par la formule (I) sont appropriés dans le traitement des troubles du système nerveux central, en particulier comme agents de lutte contre les récepteurs de 5-HT1A(5-hydroxytryptamine).
PCT/US1991/000018 1990-01-11 1991-01-08 NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL WO1991011435A2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
DK91902598T DK0510068T3 (da) 1990-01-11 1991-01-08 Nye 6,7,8,9-tetrahydro-3H-benz(e)indol-heterocycler med virkning på centralnervesystemet
EP91902598A EP0510068B1 (fr) 1990-01-11 1991-01-08 NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL
DE69131123T DE69131123T2 (de) 1990-01-11 1991-01-08 6,7,8,9-tetrahydro-3h-benz(e)indolheterocyclen mit wirkung auf das zentrale nervensystem
JP3502958A JP3049089B2 (ja) 1990-01-11 1991-01-08 新規な中枢作用性の６，７，８，９―テトラヒドロ―３Ｈ―ベンズ［ｅ］インドールヘテロ環式化合物
US07/907,932 US5288748A (en) 1990-01-11 1992-07-01 Centrally acting 6,7,8,9-tetrahydro-3H-benz(e)indole heterocyclics
KR1019920701635A KR100196887B1 (en) 1990-01-11 1992-07-10 New centrally acting 6,7,8,9-tetrahydro-3h-benz(e) indole heterocyclics
US08/144,857 US5461061A (en) 1990-01-11 1993-10-28 Centrally acting 6,7,8,9-tetrahydro-3H-benz(E)indole heterocyclics
US08/460,449 US5650427A (en) 1990-01-11 1995-06-02 Centrally acting 6,7,8,9-tetrahydro-3H-benz(e) indole heterocyclics
KR1019980710454A KR100201012B1 (en) 1990-01-11 1998-12-16 New centrally acting 6,7,8,9-tetrahydro-3h-benz(e)indole heterocyclics
GR990401483T GR3030389T3 (en) 1990-01-11 1999-06-01 NEW CENTRALLY ACTING 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE HETEROCYCLICS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46412690A 1990-01-11 1990-01-11
US464,126 1990-01-11

Publications (2)

Publication Number Publication Date
WO1991011435A2 WO1991011435A2 (fr) 1991-08-08
WO1991011435A3 true WO1991011435A3 (fr) 1991-09-05

Family

ID=23842674

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/000018 WO1991011435A2 (fr) 1990-01-11 1991-01-08 NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL

Country Status (12)

Country Link
US (3) US5288748A (fr)
EP (1) EP0510068B1 (fr)
JP (1) JP3049089B2 (fr)
KR (2) KR100196887B1 (fr)
AT (1) ATE178893T1 (fr)
AU (1) AU639301B2 (fr)
CA (1) CA2073340C (fr)
DE (1) DE69131123T2 (fr)
DK (1) DK0510068T3 (fr)
ES (1) ES2130135T3 (fr)
GR (1) GR3030389T3 (fr)
WO (1) WO1991011435A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991011435A2 (fr) * 1990-01-11 1991-08-08 The Upjohn Company NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL
US5248691A (en) * 1992-09-03 1993-09-28 Eli Lilly And Company Furanoindolines
GB9223153D0 (en) * 1992-11-05 1992-12-16 Wyeth John & Brother Ltd Piperazine derivatives
JP3298885B2 (ja) * 1993-03-25 2002-07-08 ファルマシア・アンド・アップジョン・カンパニー ドーパミン作働性活性を有するインドールテトラリン類
US5512566A (en) * 1993-10-25 1996-04-30 Ortho Pharmaceutical Corporation Tricyclic compounds having affinity for the 5-HT1A receptor
GB9407919D0 (en) * 1994-04-21 1994-06-15 Glaxo Group Ltd Chemical compounds
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
DE60041399D1 (de) * 1999-05-19 2009-03-05 Painceptor Pharma Corp Hemmer der protonenabhängigen kationenkanäle und deren verwendung in der behandlung von ischemiebedingten erkrankungen
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
DE10121217A1 (de) 2001-04-30 2002-10-31 Merck Patent Gmbh 6H-Oxazolo[4,5-e]indol-Derivate als nikotinische Acetylcholinrezeptor Liganden und/oder serotonerge Liganden
US6903110B2 (en) 2001-07-25 2005-06-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-6H-5-oxa-1-aza-phenanthrene
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
US7227023B2 (en) 2003-04-30 2007-06-05 Wyeth Quinoline 3-amino chroman derivatives
TW200524864A (en) * 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
HRP20030958A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1,3-DIAZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
HRP20030959A2 (fr) * 2003-11-21 2005-10-31 Pliva-Istra�iva�ki institut d.o.o.
HRP20030957A2 (en) * 2003-11-21 2005-08-31 Pliva-Istra�iva�ki institut d.o.o. USE OF 1-THIA-3-AZA-DIBENZO[e,h]AZULENES FOR THE MANUFACTURE OF PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
AU2006259294A1 (en) * 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists
AR063984A1 (es) * 2006-11-28 2009-03-04 Wyeth Corp Metabolitos de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina, metodos de preparacion, su uso en la fabricacion de medicamentos para el tratamiento de trastornos relacionados con 5-ht1a, composicion farmaceutica que los comprende, compuestos radioetiquetados derivado
KR102105539B1 (ko) 2020-01-15 2020-04-28 김덕군 카메라 모듈 조립용 볼 공급장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370341A (en) * 1980-12-11 1983-01-25 Ayerst, Mckenna & Harrison, Ltd. 6,7,8,9-Tetrahydro-3H-benz[E]indol-8-amine derivatives

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5117717B2 (fr) * 1971-08-23 1976-06-04
US4060626A (en) * 1972-01-26 1977-11-29 Boehringer Mannheim G.M.B.H. Indole-carboxylic carbon compounds and pharmaceutical compositions containing them
DE2740836A1 (de) * 1977-09-10 1979-03-22 Troponwerke Gmbh & Co Kg Anellierte indolderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4510157A (en) * 1982-12-27 1985-04-09 Ayerst, Mckenna & Harrison, Inc. 6,7,8,9-Tetrahydro-1H-benz(g)indol-8-amine derivatives
DE3333994A1 (de) * 1983-09-21 1985-04-04 Troponwerke GmbH & Co KG, 5000 Köln Neue pyridoindolderivate, verfahren zu ihrer herstellung und ihre verwendung
JPS6164173U (fr) * 1984-09-28 1986-05-01
JPS6475466A (en) * 1987-09-16 1989-03-22 Agency Ind Science Techn Indole derivative and production thereof
CA2057912C (fr) * 1989-07-13 1996-10-29 Chiu-Hong Lin Derives de (1,2,n) et (3,2n)-carbocyclique-2-aminotetraline
US5486611A (en) * 1989-07-13 1996-01-23 The Upjohn Company Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives
US5061711A (en) * 1989-10-09 1991-10-29 Mitsubishi Gas Chemical Company, Inc. Method of curing liver diseases by using pyrrolo quinoline quinone triesters and novel pyrrolo quinoline quinone triesters
WO1991011435A2 (fr) * 1990-01-11 1991-08-08 The Upjohn Company NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL
EP0594593A1 (fr) * 1990-03-15 1994-05-04 PHARMACIA & UPJOHN COMPANY Composes d'indole heterocycliques therapeutiquement utiles
US5223527A (en) * 1991-07-09 1993-06-29 Neurosearch A/S Isatineoxime derivatives and their use
TW239127B (fr) * 1991-12-20 1995-01-21 Hoffmann La Roche

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370341A (en) * 1980-12-11 1983-01-25 Ayerst, Mckenna & Harrison, Ltd. 6,7,8,9-Tetrahydro-3H-benz[E]indol-8-amine derivatives

Also Published As

Publication number Publication date
US5288748A (en) 1994-02-22
ES2130135T3 (es) 1999-07-01
KR927003586A (ko) 1992-12-18
AU7175491A (en) 1991-08-21
DE69131123D1 (de) 1999-05-20
JPH05503698A (ja) 1993-06-17
EP0510068A1 (fr) 1992-10-28
US5650427A (en) 1997-07-22
ATE178893T1 (de) 1999-04-15
GR3030389T3 (en) 1999-09-30
EP0510068B1 (fr) 1999-04-14
KR100196887B1 (en) 1999-06-15
DE69131123T2 (de) 1999-09-30
KR100201012B1 (en) 1999-06-15
AU639301B2 (en) 1993-07-22
WO1991011435A2 (fr) 1991-08-08
US5461061A (en) 1995-10-24
JP3049089B2 (ja) 2000-06-05
CA2073340C (fr) 1997-05-20
DK0510068T3 (da) 1999-10-25

Similar Documents

Publication Publication Date Title
WO1991011435A3 (fr) NOUVEAUX COMPOSES HETEROCYCLIQUES DE 6,7,8,9-TETRAHYDRO-3H-BENZ(e)INDOLE AGISSANT SUR LE SYSTEME NERVEUX CENTRAL
TW369526B (en) Diazabicyclic neurokinin antagonists
ATE201669T1 (de) Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten
HUT56368A (en) Process for producing tricyclic compounds and pharmaceutical compositions comprising such compounds
HUT61543A (en) Process for producing serotonin antagonist indole derivatives and pharmaceutical compositions comprising same as active ingredient
TW341565B (en) Indole derivatives processes and intermediates for their preparation and pharmaceutical compositions containing them
NO176094C (no) Analogifremgangsmåte for fremstilling av ringsubstituerte 2-amino-1,2,3,4-tetrahydronaftalener
DE69529418D1 (de) Cyclopropachromencarbonsäure derivate
NZ331613A (en) Piperazinyl or piperidinyl substituted 1,2,3,4-tetrahydronaphthalene derivatives
IL106387A (en) Indole derivatives, their preparation and pharmaceutical compositions containing them
MY131641A (en) Indoline derivatives, process of preparation and use
ZA949226B (en) Substituted 2ss-morpholino-androstane derivatives.
GB8904551D0 (en) Chemical compounds
MY131762A (en) Pharmaceutical compounds
WO1996005166A1 (fr) Derive d'amine substitue et composition medicamenteuse le contenant
ES459865A1 (es) Procedimiento para preparar nuevos derivados de indol.
GR3025257T3 (en) Quinoxalinedione derivatives as eaa antagonists.
NO20023041L (no) Fremgangsmåte for fremstilling av pyrazolopyridazinderivater
EP0276163A3 (en) Indole derivatives
HUP0000783A2 (hu) N-(piridinil-amino)-izoindolinok és származékaik, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69000806D1 (de) Indol-derivate.
ES2056025A1 (es) Nuevos derivados de indol.
AU561092B2 (en) N-(2,6 disubstituted aromatic)-n:-pyridinyl ureas

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1991902598

Country of ref document: EP

AK Designated states

Kind code of ref document: A2

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.18/91,UNDER PUBLISHED REPLACE "A1" BY "A2"

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BB BG BR CA FI HU JP KP KR LK MC MG MW NO RO SD SU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2073340

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1991902598

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991902598

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载